Puma Biotechnology Inc. buy michaelkr
Start price
14.08.24
/
50%
€2.49
Target price
14.08.25
-
Performance (%)
-0.88%
Price
14.08.24
€2.47
Summary
This prediction is currently active. The BUY prediction by michaelkr for Puma Biotechnology Inc. is nearly unchanged. This prediction currently runs until 14.08.25. The prediction end date can be changed by michaelkr at any time. michaelkr has 50% into this predictionPuma Biotechnology is a publicly traded biopharmaceutical company that develops innovative cancer therapies targeting the most aggressive and difficult-to-treat forms of the disease. Puma's lead product is Nerlynx, an oral medication approved for the treatment of HER2-positive breast cancer, and the company also has a number of other promising drugs in its pipeline. Founded in 2010, Puma is headquartered in Los Angeles, California, and its shares trade on the NASDAQ exchange under the ticker symbol PBYI.
Performance without dividends (%)
| Name | 1w |
|---|---|
| Puma Biotechnology Inc. | -0.88% |
| iShares Core DAX® | 2.687% |
| iShares Nasdaq 100 | 5.569% |
| iShares Nikkei 225® | 3.756% |
| iShares S&P 500 | 3.959% |
Comments by michaelkr for this prediction
In the thread Puma Biotechnology Inc. diskutieren
Buy Puma Biotechnology Inc.
Stopped prediction by michaelkr for Puma Biotechnology Inc.
Puma Biotechnology Inc.
Start price
Target price
Perf. (%)
€2.86
28.11.21
28.11.21
-
28.11.22
28.11.22
-13.18%
12.12.21
12.12.21
